SBWire

Global Market Direct's pharmaceuticals report, "GlycoVaxyn AG - Product Pipeline Review - 2013" provides data on the GlycoVaxyn AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis. Allergic Rhino-Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Cellulite - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cellulite, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cellulite. Cellulite - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "GinkgoPharma Co. Ltd. - Product Pipeline Review - 2013" provides data on the GinkgoPharma Co. Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Global Market Direct's pharmaceuticals report, "Foresee Pharmaceuticals, LLC - Product Pipeline Review - 2013" provides data on the Foresee Pharmaceuticals, LLC's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Hypoglycemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hypoglycemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypoglycemia. Hypoglycemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Maruishi Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013" provides data on the Maruishi Pharmaceutical Co., Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Artielle ImmunoTherapeutics, Inc. - Product Pipeline Review - 2013" provides data on the Artielle ImmunoTherapeutics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, packaging innovations, economic/lifestyle influences, distribution or pricing issues. Forecasts illustrate how the market is set to change.

Global Market Direct's pharmaceuticals report, "Zambon Company S.p.A. - Product Pipeline Review - 2013" provides data on the Zambon Company S.p.A.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Almac Discovery Ltd. - Product Pipeline Review - 2013" provides data on the Almac Discovery Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Relevare Pharmaceuticals Ltd. - Product Pipeline Review - 2013" provides data on the Relevare Pharmaceuticals Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "XTL Biopharmaceuticals Ltd. - Product Pipeline Review - 2013" provides data on the XTL Biopharmaceuticals Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "M et P Pharma AG - Product Pipeline Review - 2013" provides data on the M et P Pharma AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "MediciNova, Inc. - Product Pipeline Review - 2013" provides data on the MediciNova, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "ActogeniX NV - Product Pipeline Review - 2013" provides data on the ActogeniX NV's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Rubella - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rubella, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rubella. Rubella - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "OncoEthix SA - Product Pipeline Review - 2013" provides data on the OncoEthix SA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Germ Cell Tumors - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Germ Cell Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Germ Cell Tumors. Germ Cell Tumors - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Laboratorios Del Dr. Esteve S.A. - Product Pipeline Review - 2013" provides data on the Laboratorios Del Dr. Esteve S.A.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Siena Biotech S.p.A. - Product Pipeline Review - 2013" provides data on the Siena Biotech S.p.A.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Cellerant Therapeutics, Inc. - Product Pipeline Review - 2013" provides data on the Cellerant Therapeutics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Primary Biliary Cirrhosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Primary Biliary Cirrhosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Biliary Cirrhosis. Primary Biliary Cirrhosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "to-BBB technologies BV - Product Pipeline Review - 2013" provides data on the to-BBB technologies BV's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.